Enspryng (satralizumab) is superior to conventional immunosuppressive therapies in reducing the risk of relapses in people with neuromyelitis optica spectrum disorder (NMOSD) for up to three years, and with a comparable safety profile, according to a real-world study. Similar results were obtained when analyzing data only from NMOSD…
relapse prevention
Newer, more potent therapies offer greater benefit than standard immunosuppressants in reducing relapse rates for people who develop neuromyelitis optica spectrum disorder (NMOSD) after the age of 50, according to a large, single-center study in China. While people with late-onset NMOSD experienced more severe symptoms at onset and during…
Ofatumumab, a medication approved for multiple sclerosis (MS), may effectively prevent relapses and disability in people with neuromyelitis optica spectrum disorder (NMOSD), according to a study in China. At their last follow-up, about 80% of the 112 patients analyzed were free from relapses, and more than 60% experienced significant reductions…
Long-term use of the approved therapy Enspryng (satralizumab) safely and effectively prevented relapses in people with neuromyelitis optica spectrum disorder (NMOSD) who have antibodies against aquaporin-4 (AQP4). That’s according to up to 8.8 years of pooled data from two placebo-controlled Phase 3 clinical trials — SAkuraStar (NCT02073279) and …
The infusion therapy Ultomiris (ravulizumab-cwvz) safely and effectively reduces the risk of a relapse in complex cases of neuromyelitis optica spectrum disorder (NMOSD) and may be combined with rituximab for short periods, a case series study shows. For four NMOSD patients at a hospital in Fujiyoshida, Japan, Ultomiris…
Treatment with Enspryng (satralizumab) allows nearly all neuromyelitis optica spectrum disorder (NMOSD) patients to remain free of relapses after six months, with many reducing their use of corticosteroids and other immunosuppressants. Nearly one-third of patients were able to stop corticosteroids, which can cause serious side effects when used…
Note: This column describes the author’s own experiences with various medication side effects. Not everyone will have the same response to treatment. Consult your doctor before starting or stopping a therapy. Living with neuromyelitis optica spectrum disorder (NMOSD) feels like navigating a series of trade-offs. One of the most…
Regular maintenance treatment with low-dose rituximab is associated with less disability and fewer relapses among people with neuromyelitis optica spectrum disorder (NMOSD) compared with receiving irregular doses of the preventive therapy, according to a two-year real-world study in China. “Regular [rituximab] treatment can significantly reduce the annual relapse rate, incidence…
Biologic immunosuppressants are more effective than conventional immunosuppressants for people with neuromyelitis optica spectrum disorder (NMSOD) with self-reactive antibodies against the AQP4 protein. That’s according to real-world data from a Japanese study comparing biologic therapies — Soliris (eculizumab), Enspryng (satralizumab), Ultomiris (ravulizumab), Uplizna (inebilizumab), and…
Early use of immunosuppressive therapy — when compared with a later treatment start — was associated with fewer relapses and reduced disability among neuromyelitis optica spectrum disorder (NMOSD) patients with self-reactive antibodies against the AQP4 protein, a study from China showed. The data demonstrated a time-dependent treatment efficacy, with…